The Pharmacy Times® Breast Cancer resource center provides clinical news and articles, coverage from conferences and meetings, links to condition-specific resources, and videos and other content.
What can we help you find?
According to the FDA, patients should be selected based on an FDA-approved companion diagnostic test.
One in 8 women will develop breast cancer within their lifetime, making it the most commonly diagnosed cancer among women.
Women diagnosed with breast cancer while breastfeeding may receive treatments that decrease milk production or are contraindicated.
Researchers found that replacing 30 minutes of inactivity with exercise significantly reduces the risk of cancer-related death.
The intent of the study was to bring awareness to the medical and nonmedical financial hardships of cancer and how they can impact the use of preventive services, since there is little research available to evaluate this topic, according to the study authors.
Abemaciclib Significantly Reduces Risk of Cancer Recurrence in People With High Risk HR-Positive, HER2-Negative Early Breast Cancer
The most common adverse reactions observed in the monarchE phase 3 trial include diarrhea, neutropenia, fatigue, infections, nausea, abdominal pain, vomiting, anemia, alopecia, decreased appetite, and leukopenia.
The updated guidelines include increased recommended physical activity levels and a growing emphasis on holistic rather than nutrient-based dietary habits.
In the new data cut-offs from both studies, the survival advantages for the combination with fulvestrant and combination with an aromatase inhibitor were shown, but major disadvantages were also evident, according to the IQWiG.
Trastuzumab deruxtecan (T-DXd) (Enhertu) demonstrated strong efficacy in a phase 2 trial for treatment of HER2-positive metastatic breast cancer.
Why was a customer prescribed an allergy medication when she was expecting a pain pill?
According to study findings published in Cancer, mammography screenings reduce the rates of advanced and fatal cancers by more than 40%.
The anti-cancer medicine venetoclax may improve the current therapy for estrogen receptor-positive (ER+) breast cancer.